The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.
Genomics plc, a UK-based precision healthcare technology developer backed by drug manufacturer Vertex Pharmaceuticals, closed a $30m funding round on Monday. F-Prime Capital, an investment affiliate of financial services and investment group Fidelity, provided the funding together with university venture fund Oxford Sciences Innovation (OSI), Foresite Capital and Lansdowne Partners. Founded in 2014, Genomics has…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.